Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-Emetics Would Be Paid Separately Under Medicare Outpatient Rule

Executive Summary

The chemotherapy-induced nausea treatments Anzemet, Kytril and Zofran would be reimbursed separately rather than bundled with a package of therapeutic services under the 2005 Medicare outpatient prospective payment system proposed rule

You may also be interested in...



Medicare Payments For Unbundled Drugs Needs Revision, MedPAC Says

The Centers for Medicare & Medicaid Services should change how it sets payments for unbundled hospital outpatient drugs once a provision in the 2003 Medicare law expires, the Medicare Payment Advisory Commission said

Medicare Payments For Unbundled Drugs Needs Revision, MedPAC Says

The Centers for Medicare & Medicaid Services should change how it sets payments for unbundled hospital outpatient drugs once a provision in the 2003 Medicare law expires, the Medicare Payment Advisory Commission said

Faslodex, Aranesp Have Special Status Under Hospital Payment Rule

CMS is proposing to allow separate Medicare payments for Faslodex, Trelstar and argatroban use in the hospital outpatient setting when the products become ineligible for "pass-through" payments in 2005

Related Content

Topics

UsernamePublicRestriction

Register

PS044490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel